Award recognises and rewards journalism that extends public awareness and understanding of COPD

Boehringer IngelheimThe independent judging panel of the Eloquium Award has today named three journalists as winners of the 2007 competition for excellence in reporting on chronic obstructive pulmonary disease (COPD) the fastest growing cause of death in the world's most advanced economies. Currently, 600 million people live with COPD which is projected to become the world’s third-leading cause of death by 2020.[1,2]

The Boehringer Ingelheim Communication Award - Eloquium - attracted submissions from 13 countries, including Brazil, Chile, China, Ecuador, England, Japan, Lebanon, Sweden and Venezuela. Entries were judged by an independent panel of global COPD experts and leading journalists.*

The three winning entries of the Eloquium Award are:

  • 1st: Annu Likkanen, Veteranen, Two cigarettes were Ulla-Britt's Undoing (Sweden)
  • 2nd: Gilson Monteiro, Rádio Eldorado, Unknown enemy (Brazil)
  • 3rd: María de los Ángeles González Izurieta, Vea, Tobacco is consuming you (Chile)

"It is important that patients seek early diagnosis and treatment for COPD and key to this is improving education and awareness about the disease," commented Professor Klaus Rabe, Chair of the Judging panel and Chairman of Pulmonology, Department of Pulmonology at Academisch Ziekenhuis Leiden, The Netherlands. "While COPD is beginning to build a warranted presence in the media, a continued and sustained presence is still needed."

Commenting on the winning entry, Patricia Reaney of ReutersHealth said, "By focusing on one woman's battle with COPD the author of the winning article showed how smoking causes the illness, its impact on a person's life and the importance of early detection and treatment to limit further lung damage."

About chronic obstructive pulmonary disease (COPD)
COPD is a progressive respiratory disease that causes significant deterioration of lung function resulting in breathlessness, activity limitation and disability associated with the disease.[3] Early diagnosis and treatment can greatly improve quality of life for COPD patients, yet many are unaware they even have the disease.[4] It has been estimated that up to 50% of Americans and 75% of Europeans with COPD are undiagnosed.[4,5]

About Eloquium
Eloquium is a communication award that is sponsored by Boehringer Ingelheim. It has been awarded to three winners each year, since its launch in 2003.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of 10.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more infomration, visit www.boehringer-ingelheim.com.

References:
[1] Murray CJL, Lopez AD. eds. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge; Harvard University Press; 1996.
[2] World Health Organization. World Health Report 2004. Statistical Annex. Annex table 2 and 3: 120-131.
[3] Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease NHLBI/WHO Workshop Report. National Institute of Health; 2005. Available at http://www.goldcopd.com.
[4] Rudolf M. The reality of drug use in COPD: The European Perspective. Chest 2000; 117:29S-32S 5 Centers for Disease Control and Prevention. Surveillance Summaries, August 2, 2002. MMWR 2002:51 (No SS-6);1.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...